Abexinostat

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Abexinostat
DrugBank Accession Number
DB12565
Background

Abexinostat has been used in trials studying the treatment of Sarcoma, Lymphoma, Leukemia, Lymphocytic, and Hodgkin Disease, among others. It is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 397.431
Monoisotopic: 397.163770853
Chemical Formula
C21H23N3O5
Synonyms
  • Abexinostat
External IDs
  • CRA 024781
  • CRA 24781
  • CRA-024781
  • PCI 24781
  • PCI-24781
  • PZP-115891
  • PZP115891

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Abexinostat is a novel histone deacetylase (HDAC) inhibitor. HDAC inhibitors target HDAC enzymes and inhibit the proliferation of cancer cells and induce cancer cell death, or apoptosis. Histone deacetylation is carried out by a family of related HDAC enzymes. Inhibition of these enzymes causes changes to chromatin structure and to gene expression patterns, which results in the inhibition of proliferation of cancer cells, and induction of apoptosis 1.

TargetActionsOrganism
UHistone deacetylase 1Not AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Abexinostat.
AdenosineThe risk or severity of QTc prolongation can be increased when Adenosine is combined with Abexinostat.
AjmalineThe risk or severity of QTc prolongation can be increased when Ajmaline is combined with Abexinostat.
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Abexinostat.
AlimemazineThe risk or severity of QTc prolongation can be increased when Alimemazine is combined with Abexinostat.
AmantadineThe risk or severity of QTc prolongation can be increased when Amantadine is combined with Abexinostat.
AmifampridineThe risk or severity of QTc prolongation can be increased when Amifampridine is combined with Abexinostat.
AmiodaroneThe risk or severity of QTc prolongation can be increased when Abexinostat is combined with Amiodarone.
AmisulprideThe risk or severity of QTc prolongation can be increased when Abexinostat is combined with Amisulpride.
AmitriptylineThe risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Abexinostat.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzofurans. These are organic compounds containing a benzene ring fused to a furan. Furan is a five-membered aromatic ring with four carbon atoms and one oxygen atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzofurans
Sub Class
Not Available
Direct Parent
Benzofurans
Alternative Parents
Benzoic acids and derivatives / Phenoxy compounds / Phenol ethers / 2-heteroaryl carboxamides / Furoic acid and derivatives / Benzoyl derivatives / Alkyl aryl ethers / Aralkylamines / Heteroaromatic compounds / Trialkylamines
show 7 more
Substituents
2-heteroaryl carboxamide / Alkyl aryl ether / Amine / Amino acid or derivatives / Aralkylamine / Aromatic heteropolycyclic compound / Benzenoid / Benzofuran / Benzoic acid or derivatives / Benzoyl
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
IYO470654U
CAS number
783355-60-2
InChI Key
MAUCONCHVWBMHK-UHFFFAOYSA-N
InChI
InChI=1S/C21H23N3O5/c1-24(2)13-17-16-5-3-4-6-18(16)29-19(17)21(26)22-11-12-28-15-9-7-14(8-10-15)20(25)23-27/h3-10,27H,11-13H2,1-2H3,(H,22,26)(H,23,25)
IUPAC Name
3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide
SMILES
CN(C)CC1=C(OC2=CC=CC=C12)C(=O)NCCOC1=CC=C(C=C1)C(=O)NO

References

General References
  1. Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, Liu L, Schultz BE, Young PR, Dalrymple SA: CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther. 2006 May;5(5):1309-17. [Article]
PubChem Compound
11749858
PubChem Substance
347828788
ChemSpider
9924562
BindingDB
24622
ChEBI
92223
ChEMBL
CHEMBL2103863
ZINC
ZINC000006716700
Wikipedia
Abexinostat

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingTreatmentRenal Cell Adenocarcinoma1
2Active Not RecruitingTreatmentFollicular Lymphoma ( FL)1
2RecruitingTreatmentDiffuse Large B-Cell Lymphoma (DLBCL)1
2RecruitingTreatmentFollicular Lymphoma ( FL)1
1CompletedTreatmentChronic Lymphocytic Leukemia (CLL) / Hodgkins Disease (HD) / Multiple Myeloma (MM) / Neoplasms by Site / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentHodgkins Disease (HD) / Leukemias / Lymphocytic / Malignant Lymphomas / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentNeoplasms / Neoplasms, Hematologic1
1RecruitingTreatmentCutaneous Melanoma, Stage III / Cutaneous Melanoma, Stage IV / Locally Advanced Melanoma / Locally Advanced Solid Neoplasm / Metastatic Head and Neck Squamous Cell Carcinoma / Metastatic Malignant Solid Neoplasm / Metastatic Melanoma / Metastatic Ureter Urothelial Carcinoma / Non-Small Cell Lung Carcinoma (NSCLC) / Stage IB Lung Cancer AJCC v7 / Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 / Stage III Lung Cancer AJCC v8 / Stage III Ureter Cancer AJCC v8 / Stage IIIA Lung Cancer AJCC v8 / Stage IIIB Lung Cancer AJCC v8 / Stage IIIC Lung Cancer AJCC v8 / Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 / Stage IV Lung Cancer AJCC v8 / Stage IV Ureter Cancer AJCC v8 / Stage IVA Lung Cancer AJCC v8 / Stage IVB Lung Cancer AJCC v81
1RecruitingTreatmentSolid Metastatic Tumor1
1WithdrawnTreatmentAnatomic Stage III Breast Cancer AJCC v8 / Anatomic Stage IIIA Breast Cancer AJCC v8 / Anatomic Stage IIIB Breast Cancer AJCC v8 / Anatomic Stage IIIC Breast Cancer AJCC v8 / Anatomic Stage IV Breast Cancer AJCC v8 / Hormone Receptor Positive Breast Carcinoma / Locally Advanced Breast Carcinoma / Metastatic Breast Carcinoma / Metastatic Endometrioid Adenocarcinoma / Metastatic Fallopian Tube Carcinoma / Metastatic HER2 Negative Breast Carcinoma / Metastatic Malignant Solid Neoplasm / Metastatic Ovarian carcinoma / Metastatic Primary Peritoneal Carcinoma / Prognostic Stage III Breast Cancer AJCC v8 / Prognostic Stage IIIA Breast Cancer AJCC v8 / Prognostic Stage IIIB Breast Cancer AJCC v8 / Prognostic Stage IIIC Breast Cancer AJCC v8 / Prognostic Stage IV Breast Cancer AJCC v8 / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Refractory Breast Carcinoma / Stage IV Fallopian Tube Cancer AJCC v8 / Stage IV Ovarian Cancer AJCC v8 / Stage IV Primary Peritoneal Cancer AJCC v8 / Stage IV Uterine Corpus Cancer AJCC v8 / Stage IVA Fallopian Tube Cancer AJCC v8 / Stage IVA Ovarian Cancer AJCC v8 / Stage IVA Primary Peritoneal Cancer AJCC v8 / Stage IVA Uterine Corpus Cancer AJCC v8 / Stage IVB Fallopian Tube Cancer AJCC v8 / Stage IVB Ovarian Cancer AJCC v8 / Stage IVB Primary Peritoneal Cancer AJCC v8 / Stage IVB Uterine Corpus Cancer AJCC v81

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0767 mg/mLALOGPS
logP1.8ALOGPS
logP1.43ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)9.83ChemAxon
pKa (Strongest Basic)8.23ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area104.04 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity108.69 m3·mol-1ChemAxon
Polarizability42.77 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Transcription regulatory region sequence-specific dna binding
Specific Function
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an impo...
Gene Name
HDAC1
Uniprot ID
Q13547
Uniprot Name
Histone deacetylase 1
Molecular Weight
55102.615 Da

Drug created on October 20, 2016 22:55 / Updated on February 21, 2021 18:53